Postoperative Analgesia in Patients With Microvascular Decompression

Efficacy and Safety of Multimodal Analgesia Used in Patients With Microvascular Decompression

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03152955

Enrollment

Registered

2017-05-15

Start date

2017-05-15

Completion date

2018-05-15

Last updated

2018-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal Neuralgia

Keywords

trigeminal neuralgia, nerve block

Brief summary

Perioperative pain is caused by a variety of harmful factors through multiple mechanisms, therefore, reasonable postoperative analgesia should be combined with drugs or measures of different mechanism , which is called multimodal analgesia. Multimodal analgesia could minimize side effects and achieve a better analgesic effect. Commonly used strategies of multimodal analgesia are oral analgesic drug, nerve block, patient controlled analgesia and so on. This study will observe the effect of multimodal analgesia on postoperative pain in patients with microvascular decompression and record side effects. Finally, it will provide technical support for the guidance of postoperative analgesia in patients of trigeminal neuralgia.

Detailed description

The investigators will collect 90 cases which will be divided into 3 groups. Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron. In Group B, patient-controlled analgesia which contains sufentanil, ondansetron and ketamine will be applied. In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.

Interventions

DRUGKetamine

Ketamine will be applied in patient-controlled analgesia.

OTHERscalp nerve block

Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.

DRUGondansetron

Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.

DRUGSufentanil

Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients of trigeminal neuralgia plan to receive microvascular decompression 2. Age between 18 and 70, ASA classification between Ⅰ～Ⅲ 3. No severe liver and kidney disease, no blood coagulation dysfunction 4. No history of long-term opioid drugs usage, no drug addiction history 5. Patients are fully conscious, cooperation, understanding and voluntarily signed informed consent

Exclusion criteria

1. More than 20% of the total blood volume is lost in operation 2. Intracranial hematoma happens within 24 h after surgery 3. Secondary surgery patients

Design outcomes

Primary

Measure	Time frame
visual analog scale score	6 hour after operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026